TissGeneSummary for ANKRD45 |
Gene summary |
Basic gene information | Gene symbol | ANKRD45 |
Gene name | ankyrin repeat domain 45 | |
Synonyms | CT117 | |
Cytomap | UCSC genome browser: 1q25.1 | |
Type of gene | protein-coding | |
RefGenes | NM_198493.2, | |
Description | ankyrin repeat domain-containing protein 45cancer/testis antigen 117 | |
Modification date | 20141207 | |
dbXrefs | HGNC : HGNC | |
HPRD : 13501 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ANKRD45 | |
BioGPS: 339416 | ||
Pathway | NCI Pathway Interaction Database: ANKRD45 | |
KEGG: ANKRD45 | ||
REACTOME: ANKRD45 | ||
Pathway Commons: ANKRD45 | ||
Context | iHOP: ANKRD45 | |
ligand binding site mutation search in PubMed: ANKRD45 | ||
UCL Cancer Institute: ANKRD45 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of ANKRD45 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for ANKRD45 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
LUSC | 0.278528748 | 2.046956199 | -1.768427451 | 2.63E-08 | 7.88E-08 |
PRAD | -0.591381697 | 0.562456764 | -1.153838462 | 1.35E-05 | 7.15E-05 |
KIRC | 0.764971722 | 2.856517555 | -2.091545833 | 8.26E-20 | 6.41E-19 |
KICH | -0.704866389 | 2.589157611 | -3.294024 | 3.63E-12 | 3.77E-11 |
COAD | -1.515695159 | -0.40238362 | -1.113311538 | 0.00515 | 0.012304962 |
LIHC | -0.926490389 | -2.043892389 | 1.117402 | 6.91E-05 | 0.000247934 |
Top |
TissGene-miRNA for ANKRD45 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for ANKRD45 |
TissGeneSNV for ANKRD45 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.G188E | SKCM | 2 |
p.S218F | SKCM | 2 |
p.E143K | SKCM | 2 |
p.L180I | DLBC | 1 |
p.R122C | SKCM | 1 |
p.A87T | SKCM | 1 |
p.L129Q | LUAD | 1 |
p.E144* | STAD | 1 |
p.E19K | SKCM | 1 |
p.E2V | BLCA | 1 |
p.M86I | BLCA | 1 |
p.G50D | SKCM | 1 |
p.G100D | UCEC | 1 |
p.E19D | UCEC | 1 |
p.Q155L | LUAD | 1 |
p.P61S | SKCM | 1 |
p.N104S | SKCM | 1 |
p.R168S | THCA | 1 |
p.A66V | STAD | 1 |
p.V252A | HNSC | 1 |
p.R259* | SKCM | 1 |
p.D196E | ESCA | 1 |
p.G77E | SKCM | 1 |
p.G188R | SKCM | 1 |
p.H115R | HNSC | 1 |
p.P235H | COAD | 1 |
p.R205H | COAD | 1 |
p.K207Q | UCEC | 1 |
p.K106T | UCEC | 1 |
p.E24G | COAD | 1 |
p.R145K | SKCM | 1 |
p.P243S | SKCM | 1 |
p.Q28R | ESCA | 1 |
p.E144X | STAD | 1 |
p.Y153* | UCEC | 1 |
p.E144Q | LUAD | 1 |
p.E73* | UCEC | 1 |
p.T215R | LUAD | 1 |
p.E29X | READ | 1 |
p.S12L | SKCM | 1 |
p.D231N | SKCM | 1 |
p.L132V | ACC | 1 |
p.A119S | LUAD | 1 |
p.R145M | COAD | 1 |
p.Q225H | PRAD | 1 |
p.E31K | LUAD | 1 |
p.E195K | SKCM | 1 |
p.P42L | SKCM | 1 |
p.A27V | SKCM | 1 |
p.L70H | SKCM | 1 |
p.K197N | STAD | 1 |
Top |
TissGeneCNV for ANKRD45 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for ANKRD45 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for ANKRD45 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for ANKRD45 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for ANKRD45 |
TissGeneDrug for ANKRD45 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for ANKRD45 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |